Sabinsa to Exhibit Branded Ingredient Portfolio and Discuss AI-Driven Clinical Trials at Vitafoods Asia 2026

Sabinsa will present a portfolio of 12 branded ingredients at Vitafoods Asia 2026, which is scheduled for September 2-4 in Bangkok, Thailand.

"Consumers across Asia-Pacific are moving past general wellness claims and asking what a product actually does for them and what evidence backs it up," noted Shaheen Majeed, the ingredient supplier’s global CEO and managing director, in the announcement.¹ The company's booth presence, one of more than 650 expected at the event, reflects a broader push among ingredient suppliers to pair regional market access with claims of scientific support.

What Is Sabinsa Featuring at Vitafoods Asia 2026?

The 12 ingredients Sabinsa plans to showcase span common supplement categories: joint and mobility support, immune and respiratory health, antioxidant and healthy-aging formulations, metabolic and blood sugar support, weight management, cognitive performance, stress and adaptogenic support, digestive health, and circulation and sports performance.

Sabinsa said its team will be available during the show to discuss country-specific regulatory requirements and product formats across Asia-Pacific markets, positioning the visit as much around market entry logistics as ingredient promotion.

Why Does Clinical Substantiation Matter in the Asia-Pacific Supplement Market?

The Asia-Pacific dietary supplements market was valued at roughly $64.5 billion in 2024, with 1 market research firm projecting growth to more than $151 billion by 2033.² That research attributes growth primarily to rising health consciousness, an aging population, and urbanization, though it also notes that quality and scientific backing are highly valued among some regional consumer segments, particularly in China. Whether demand for clinical evidence is now a leading purchase driver across the broader region, as Majeed's comments suggest, is not something the available market data confirms uniformly.

What Might AI-Driven Clinical Trials Mean for Supplement Development?

Majeed's panel, "Evidence to Impact: How AI-Driven Clinical Trials are Reshaping Innovation," addresses a topic with regulatory precedent in adjacent industries. The FDA issued draft guidance in January 2025 on using artificial intelligence to support regulatory decisions for drug and biological products, establishing a risk-based framework for evaluating whether an AI model's output can be trusted for a given use.³

That guidance applies to drugs and biologics rather than dietary supplements, which follow a different regulatory pathway in the United States, but it reflects a broader industry conversation about how AI tools are being incorporated into clinical research design and evidence generation, a conversation the panel appears intended to extend into the supplement sector specifically.

What Remains Unclear About the Panel's Framing?

The announcement does not specify what "AI-driven clinical trials" means in practice for Sabinsa's own ingredient research, nor does it cite published methodology or peer-reviewed data describing how artificial intelligence has been applied to any of the company's studies. The panel description points to potential outcomes, including new market opportunities and measurable return on investment, that are business rather than clinical endpoints.

Manufacturers interested in the topic will likely need more specific detail from the session itself, or from subsequent published research, before treating "AI-driven" claims as a substitute for standard clinical evidence review. As with many trade-show panel descriptions, the framing here is forward-looking rather than a report on completed findings, and its practical relevance to individual ingredient substantiation will depend on details not yet public.

References

1. Sabinsa's active nutrition ingredients take center stage at Vitafoods Asia 2026. Sabinsa. August 24, 2026. Accessed August 25, 2026. Press release provided via email.

2. Asia Pacific Dietary Supplements Market Size Report, 2033. Grand View Research. Published July 2025. Accessed August 24, 2026. https://www.grandviewresearch.com/industry-analysis/asia-pacific-dietary-supplements-market-report

3. Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products. US Food and Drug Administration. January 2025. Accessed August 24, 2026. https://www.fda.gov/media/184830/download